Loading stock data…
Revolution Medicines (RVMD)
$189.23+0.48 (+0.25%)
Market ClosedLast close Jul 24
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Revolution Medicines, Inc. in the Healthcare sector is trading at $189.23 with a market capitalization of $33.2B. Wall Street consensus targets $207.00 (21 analysts), implying a +9.4% move over the next 12 months. The stock is currently near its 52-week high of $193.82, remaining 69.0% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +9.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$445.22M↓ | -$361.63M↓ | -$315.27M↓ | -$264.71M↓ | -$240.76M |
| Net Income | -$453.82M↓ | -$364.89M↓ | -$305.21M↓ | -$247.79M↓ | -$213.42M |
Peer Comparison
JNJUNHPFE
Fundamentals
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as m...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$33.17B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-91.45%
Volume
Today's trading volume
1.23M
Recent News
Will FDA Priority Review for Daraxonrasib Redefine Revolution Medicines' (RVMD) Pancreatic Cancer Narrative?
Revolution Medicines recently reported that the FDA accepted its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, after the Phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma met all primary and key secondary endpoints with improved survival, quality of life and a manageable safety profile. The same data earned daraxonrasib priority pathways on both sides of the Atlantic, including the FDA Commissioner’s National...
Revolution Medicines (RVMD) Stock Looks Fully Priced With Strong Returns But Weak Value Checks
Revolution Medicines stock has delivered very strong returns in recent years, yet its current valuation checks lean expensive. This sets up a clear tension between the share price momentum and what the broader metrics suggest about value. Revolution Medicines has returned about 6.4x over the past 3 years, which puts extra pressure on the current share price to be supported by the business outlook. The FDA review of daraxonrasib, supported by trial results in pancreatic cancer, can underpin...
Revolution Medicines (RVMD) Wins FDA Review Milestone For Daraxonrasib In Pancreatic Cancer
Revolution Medicines (NasdaqGS:RVMD) reported that the FDA has accepted its New Drug Application for daraxonrasib following strong Phase 3 results. Daraxonrasib has been selected for the FDA Commissioner's National Priority Voucher program, with U.S. regulatory review now formally underway. Regulatory assessment for daraxonrasib has also started in Europe, with both U.S. and European authorities reviewing the treatment for pancreatic cancer. Revolution Medicines focuses on targeted oncology...
Can Revolution Medicines (RVMD) Justify Its Valuation On Daraxonrasib Survival Data?
Revolution Medicines (RVMD) drew fresh attention after reporting that its experimental treatment daraxonrasib nearly doubled survival for pancreatic cancer patients who had exhausted other options, raising questions about how this data might influence the stock. See our latest analysis for Revolution Medicines. The survival data for daraxonrasib has arrived alongside strong recent trading in Revolution Medicines, with the share price returning 39.86% over 90 days and a year to date share...
Big pharma’s patent cliff meets a new biotech Cold War: We need to outrun China, not outlaw it
If we slash federal research budgets, we risk hamstringing our scientists and losing an otherwise winnable race.